Tech Company Financing Transactions
Ceptaris Therapeutics Funding Round
Ceptaris Therapeutics, operating out of Malvern, secured $10 million in funding from Aperture Venture Partners, BioAdvance Ventures and Burrill & Company.
Transaction Overview
Company Name
Announced On
6/5/2012
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series D
Investors
Proceeds Purpose
The funding will be used for operational expenses, including activities related to addressing the FDA's requests.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Tullman
Chief Medical Officer
Jeffrey Wilkins
Chief Operating Officer
Douglas Gssl
VP - Bus. Development
Evan Dick
VP - General Counsel
Kamil Ali-Jackson
VP - Operations
Jeffrey Shaver
VP - R & D
Timothy Henkel
Browse more venture capital transactions:
Prev: 6/5/2012: Clarizen venture capital transaction
Next: 6/5/2012: Smarterer venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs